A Clinical Trial of Soluble Fiber for Asthma
Launched by PHOENIX CHILDREN'S HOSPITAL · Apr 12, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether adding a type of soluble fiber, called NOVELOSETM 3490, can help improve asthma symptoms in children aged 6 to 17. The researchers want to learn how diet, specifically fiber intake, might affect asthma by looking at samples from participants, such as blood, stool, and nasal wash. If your child is eligible for the study, they will be randomly assigned to receive either the soluble fiber or a placebo (a drink with no active ingredient) for several weeks. Participants will also fill out a dietary questionnaire to assess their fiber intake.
To be eligible, your child should have been diagnosed with asthma in the last two years and must meet certain health criteria, including having a specific level of a marker in their breath that indicates asthma severity. They should not have had any emergency visits for asthma in the past month and must be able to return for a follow-up visit after 4 to 6 weeks. This trial is still recruiting, so if you're interested, it's a good opportunity to learn more about how diet might play a role in managing asthma.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between ages 6-17
- • Asthma diagnosis within the last 2 years
- • Fractional excretion of exhaled nitric oxide (FeNO) \> 50 ppb OR a clinical history of environmental allergies as defined by a positive skin prick or positive specific immunoglobulin E (IgE) tests to aeroallergens
- • No emergency department visits in the past 1 month
- • Ability to consume a liquid drink of fiber or placebo
- • Ability to return for a 4-6 week follow-up visit
- • No special or unique diet
- Exclusion Criteria:
- • Cystic fibrosis
- • Bronchiectasis
- • Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks
- • Baseline estimated daily fiber intake less than or equal to 16 grams as determined by the ASA 24
- • Sibling of a participant already enrolled in the study
About Phoenix Children's Hospital
Phoenix Children's Hospital is a leading pediatric healthcare institution dedicated to advancing child health through innovative research and clinical trials. With a commitment to providing exceptional care, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous clinical studies that aim to improve treatment outcomes and enhance the quality of life for children facing various health challenges. As a recognized center of excellence, Phoenix Children's Hospital collaborates with a network of healthcare professionals, researchers, and academic institutions to foster groundbreaking discoveries and ensure access to cutting-edge therapies for young patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Patients applied
Trial Officials
Matthew Rank
Principal Investigator
Phoenix Children's
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported